Ribomic

Ribomic Operating Cash Flow

The Operating Cash Flow of Ribomic (4591.T) as of Oct 30, 2026 is -1.11 B JPY. In the previous year, Operating Cash Flow was -996.97 M JPY — a change of 11.42% (lower).

Operating Cash Flow

-1.11 BJPY

YoY

11.42%

Last updated:

Operating Cash Flow of Ribomic is 2026 -1.11 B JPY. Operating Cash Flow of Ribomic was 2025 -996.97 M JPY. It decreases by 11.42% lower compared to the previous year.

The Ribomic Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2019
-830.46 M JPY
Jan 1, 2020
-902.29 M JPY
Jan 1, 2021
-1.15 B JPY
Jan 1, 2022
-1.50 B JPY
Jan 1, 2023
-1.71 B JPY
Jan 1, 2024
-932.76 M JPY
Jan 1, 2025
-996.97 M JPY
Jan 1, 2026
-1.11 B JPY
The Ribomic Operating Cash Flow history
YEAROperating Cash FlowYoY
-1.11 BJPY+11.42%
-996.97 MJPY+6.88%
-932.76 MJPY-45.41%
-1.71 BJPY+13.97%
-1.50 BJPY+30.48%
-1.15 BJPY+27.35%
-902.29 MJPY+8.65%
-830.46 MJPY+19.53%
-694.80 MJPY-1.71%
-706.89 MJPY+117.70%
-324.70 MJPY-341.26%
134.58 MJPY-182.81%
-162.53 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

Operating Cash Flow of Ribomic is -1.11 B JPY in 2026.

Operating Cash Flow of Ribomic changed from -996.97 M JPY to -1.11 B JPY, representing a 11.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Ribomic since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Ribomic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ribomic

All Key Metrics — Ribomic